More than a thousand more drugs will be discontinued in hospitals

"Pharmaceutical Network Industry Dynamics" Recently, Anhui Province pharmaceutical centralized procurement platform issued "on the public suspension of procurement part of the second batch of national drug centralized procurement (Anhui) related to the failure to evaluate the quality of generic drugs and efficacy consistent notice."
, a total of 1080 drugs that failed to pass a consistent evaluation were suspended from the procurement process.
there are more than a thousand drugs, will stop selling in hospitals (Photo: Pharmaceutical Network) In this regard, the industry believes that, in the context of national collection, with the continued promotion of generic consistent evaluation policy, a large number of varieties will face market restrictions or even exit from the market.
fact, according to the relevant data can be clearly found that this year, in addition to Anhui Province, there is no consistent evaluation of the varieties can be said to have ushered in a wave of withdrawal throughout the country.
e.g. on April 13, the Beijing Pharmaceutical Collection service center issued a "notice on the suspension of the national collection within the scope of partial failure to pass the consistent evaluation of product procurement functions", suspended procurement of more than 800 varieties, involving a number of well-known pharmaceutical companies, such as Jiangsu Hengrui, Shi pharmaceutical Ouyi, Sichuan Colum, Shijiazhuang Four Medicines, Lizhu Group, Medicine and so on.
April 17, Jiangsu Provincial Public Resources Trading Center issued a "Notice on the public suspension of the procurement of some of the failed generic drug quality and efficacy evaluation of drugs", suspended the procurement of 152 drugs, including amosicillin capsules, omeprazole intestinal capsules, oxalic acid aspirin tablets, meloxicon tablets, sodium bicarbonate tablets, cephalosporine capsules, zoacetamin tablets and so on.
July, Shaanxi Province's centralized drug procurement platform issued the "Announcement on the central procurement and use of drugs by state organizations to expand the scope of the relevant varieties in the region (II)."
, 7 drugs through the audit to meet the requirements of the network, 24 drugs due to over-evaluation of more than 3 were disqualified.
From the above can be seen, for clinical commonly used drugs in the local harvesting trend, the practice of local collection seems to prove that the unseeded varieties, not consistent evaluation of drugs in market share and price will inevitably be subject to a greater degree of loss, especially in the non-consistent evaluation of varieties.
In fact, as early as March 5, 2016, the State issued the Opinions on the Conduct of Consistent Evaluation of the Quality and Efficacy of Generic Drugs (State Office Issued No. 8 of 2016), which explicitly requires that more than 3 production enterprises with the same drug through conformity evaluation will no longer select varieties that have not passed the consistent evaluation in the area of centralized drug procurement.
means that once the consistency evaluation of this variety has been completed three pharmaceutical companies, not consistent evaluation of the variety, will face the loss of the hospital market.
, it can be said that the pace and progress of consistent evaluation is increasingly becoming a factor in the rapid and slow withdrawal of pharmaceutical companies from the market.
present, with more and more varieties through consistent evaluation, the first family after the evaluation of the three-year period, for many pharmaceutical companies, is pressure, but also the driving force of continuous progress.
in the evaluation of the loss of not only the hospital market, it is likely that even the drug approval is not guaranteed, many pharmaceutical companies have become more and more aware that generic consistent evaluation is the general trend.
not only to do, but also to do it early.